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Background: Gastroesophageal reflux disease (GERD) is a common cause of chronic cough. Both acid and nonacid
reflux is thought to play a role in the initiation of coughing and cough hypersensitivity. The GABAB receptor agonist
lesogaberan was developed as a peripherally restricted anti-reflux therapy that reduces the frequency of transient
lower esophageal sphincter relaxations (TLESR; the major cause of reflux) in animals and in patients with GERD.
GABAB receptor agonists have also been shown to possess antitussive effects in patients and in animals
independent of their effects on TLESR, suggesting that lesogaberan may be a promising treatment for chronic
cough.
Methods: We have assessed the direct antitussive effects of lesogaberan (AZD3355). The effects of other GABAB
receptor agonists were also determined. Coughing was evoked in awake guinea pigs using aerosol challenges with
citric acid.
Results: Lesogaberan dose-dependently inhibited citric acid evoked coughing in guinea pigs. Comparable effects
of the GABAB receptor agonists baclofen and 3-aminopropylphosphinic acid (3-APPiA) on cough were also
observed. Baclofen produced obvious signs of sedation and respiratory depression. By contrast, both lesogaberan
and 3-APPiA (both inactivated centrally by GABA transporters) were devoid of sedative effects and did not alter
respiratory rate.
Conclusions: Together, the data suggest that lesogaberan and related GABAB receptor agonists may hold promise
as safe and effective antitussive agents largely devoid of CNS side effects.
Keywords: Gastroesophageal reflux, Esophagus, LES relaxation, C-fiber, TRPV1, LesogaberanCough is one of the most commonly reported symptoms
amongst patients seeking medical advice. Acute cough is
triggered primarily by viral infections, while the most
common causes of chronic cough are asthma, upper air-
way inflammatory disorders, and gastroesophageal reflux
disease (GERD). Therapeutics used specifically for the
treatment of cough are either minimally effective or have
unwanted side effects that limit their utility. In patients* Correspondence: bjc@jhmi.edu
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reproduction in any medium, provided the orwith chronic cough, treatment of their underlying disease
can improve patient quality of life and reduce coughing.
But for many patients with chronic, troublesome cough,
even after aggressive medical treatment of their underlying
illnesses, cough can remain a significant health problem
that adversely impacts quality of life. New and more ef-
fective and selective treatments for cough thus represent
an unmet need in respiratory medicine [1,2].
Agonists of the metabotropic GABAB receptor such as
baclofen have been evaluated for their utility in targeting
a number of peripheral disorders thought to involve
aberrant reflexes and sensations including pain, overactivel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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GABAB receptor agonists have also been evaluated for
their effects on airways hyperresponsiveness, GERD and
cough [11-20]. Although clinical benefit has been reported
in these latter studies, a sedative effect of baclofen has also
been noted [21,22]. Ideally, an effective treatment for
cough would prevent cough through direct effects on sen-
sory nerves innervating the airways and independent of
any significant CNS-dependent side effects. A therapy that
targets both cough and GERD would be especially desi-
rable, given the association between these conditions.
Key to the side effect profile of systemically adminis-
tered GABAB receptor agonists is their CNS penetrance
and susceptibility to inactivation by uptake [23,24].
GABA and analogs of GABA are subject to uptake in
the central nervous system by the 4 identified GABA
transporters (GAT1-GAT4). Baclofen is not a substrate
for uptake and can act centrally when administered
peripherally [25]. By contrast, 3-APPiA is a GABAB
receptor agonist that is inactivated centrally by trans-
port [24-26]. There are reports of antitussive effects of
3-APPiA in guinea pigs and cats [27,28]. It is thus
possible that GABAB receptor agonists work periphe-
rally to prevent vagal reflexes.
Lesogaberan (AZD3355) is a GABAB receptor agonist
with limited CNS side effects that was developed for the
treatment of GERD [20,25,29-31]. Like 3-APPiA, lesoga-
beran is inactivated centrally by GAT-dependent trans-
port [25]. The purpose of this study was to evaluate theFigure 1 A representative trace of coughing evoked by a citric acid c
produce a negative pressure in the chamber, with expiratory (E) efforts pro
respiratory rate at the outset of each experiment (breaths/ min), the time t
to Peak (P-P) pressures associated with cough (measured by comparing the
of the P-P pressures measured at eupnea), the total number of coughs evo
evoked cumulatively by all doses of citric acid studied.effects of lesogaberan and other GABAB receptor ago-
nists on citric acid induced coughing in guinea pigs.Methods
The institutional animal care and use committee
approved all of the studies described below. Male Hartley
guinea pigs (200-400 g, Charles River) were placed in a
flow through chamber filled with air by an air pump. A
pressure transducer was connected to the outflow of the
chamber to monitor respiratory efforts and coughing in
response to citric acid challenge. Data was recorded digi-
tally using a Biopac data acquisition system.
Guinea pigs were pretreated 30 minutes prior to citric
acid challenge with vehicle, lesogaberan (0.3-10 mg/ kg),
baclofen (0.3 and 3 mg/ kg), 3-APPiA (0.3 and 3 mg/ kg)
or SKF97541 (0.1 and 0.3 mg/ kg), administered by sub-
cutaneous injection. After a 10 minute equilibration
period in the exposure chamber when basal respiratory
rate was monitored, guinea pigs were then challenged
with increasing concentrations of citric acid (0.01, 0.1,
0.3 and 1 M), delivered by nebulizer (particle size: <5
μm) connected in series with the air pump. Each dose
was delivered for 5 minutes, with a 5 minute interval in
between doses. The total number of coughs evoked by
each concentration of citric acid both during the 5 minute
challenge and during the 5 minutes following the chal-
lenge was determined. The results of these studies are pre-
sented as the cumulative number of coughs evoked.hallenge to an awake guinea pig is depicted. Inspiratory (I) efforts
ducing positive pressures. These traces were used to measure
o first cough following initiation of the citric acid challenges, the Peak
P-P pressures associated with coughing, expressed as a percentage
ked by each dose of citric acid and the total number of coughs
Figure 2 GABAB receptor agonists have differential effects on
respiratory rate in awake guinea pigs. Each bar represents the
mean ± sem of 5–15 experiments. An asterisk (*) indicates that
the treatment reduced respiratory rate relative to that measured in
animals pretreated with vehicle (p < 0.05).
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pressure changes in the chamber, reflecting an enhanced
inspiratory effort followed by a forceful expiratory effort,
with expiratory pressure changes ≥ 500% of the pres-
sures associated with expiration during eupnea, all oc-
curring in less than 1 second. Coughing is readily
differentiated from enhanced breaths (sighs), often asso-
ciated with stimuli inducing bronchospasm, which have
a roughly symmetric pressure signature (with equally
enhanced inspiratory and expiratory pressures) and
slower cycle (Figure 1). In these healthy, young animals
and with the cough evoked by citric acid aerosols, the tus-
sive responses evoked were presumed and indeed likely to
be the result of a direct effect of the citric acid on airway
sensory nerves. By extension, any antitussive effects of the
compounds studied were likely to be the result of a direct
effect on cough, and not the consequence of any effects
on underlying pathology (e.g. GERD).
The results are presented as a mean ± sem of n experi-
ments, where n is the number of guinea pigs studied.
Guinea pigs were challenged only once (to each dose of
citric acid) in this unpaired experimental design. Differ-
ences amongst group means were evaluated by 1 way
analysis of variance. A p-value of less than 0.05 was con-
sidered significant.
Reagents
Baclofen and citric acid were purchased from Sigma
(St. Louis, MO). AstraZeneca (Mölndal, Sweden) provided
lesogaberan, 3-APPiA and SKF97541. All reagents were
dissolved in 0.9% NaCl solution.
Results
Baseline respiratory rate in control animals averaged 96 ±
1 breaths/ min (n = 15). At a dose of 3 mg/ kg, both baclo-
fen and SKF97541 reduced baseline respiratory rate (78 ±
7 and 69 ± 3 breaths/ min, respectively; n = 5-6; p <
0.05) and produced obvious signs of sedation and le-
thargy. By contrast, 3 mg/ kg 3-APPiA and lesogaberan,
even up to a dose of 10 mg/ kg, were without effect on
respiratory rate (98 ± 2 and 97 ± 1 breaths/min, re-
spectively; n = 7-8; p > 0.1) and produced no other
overt signs of sedation or lethargy (Figure 2).
Citric acid inhalation evoked concentration-dependent
coughing in the awake guinea pigs. No animals in any of
the treatment groups coughed in response to the citric
acid vehicle (water) inhalation, while 56/61 animals
coughed at least once to 0.3 M citric acid challenge. The
highest concentration of citric acid was not always well-
tolerated. Five-minute challenges with 1 M citric acid
were interrupted in 2/15 control experiments due to
labored breathing. All but 3 of 41 animals pretreated
with baclofen, 3-APPiA or lesogaberan completed the 1
M citric acid challenges. The coughing evoked by citricacid had a characteristic pattern of single, powerful
coughs, occasionally 2 on consecutive breaths, but never
the paroxysmal coughing we reported previously in stu-
dies of bradykinin evoked coughing [32,33]. No signs of
tachyphylaxis were apparent in these studies. Thus, if a
robust cough response was evoked by a lower concentra-
tion of citric acid, subsequent challenge with a higher
dose of citric acid still evoked coughing.
Baclofen, 3-APPiA and lesogaberan all inhibited citric
acid induced coughing (Figure 3). The effects of all of
these drugs were found to be dose-dependent. Lesoga-
beran was equipotent to baclofen in these studies (but,
as mentioned above, without coincident sedative effects
and respiratory depression). The sedating effects of
SKF97541 were so profound that its antitussive actions
were not extensively studied. Baclofen, 3-APPiA and leso-
gaberan all slightly reduced the percentage of animals
coughing to any given dose of citric acid, and reduced the
number of coughs evoked by given doses of citric acid.
None of the drugs studied had any pronounced effects on
the time to onset of coughing, nor on the peak pressures
produced during the cough (Table 1).
Discussion
Lesogaberan is a GABAB receptor agonist with a limited
CNS side effect profile. This compound has been evalu-
ated as a treatment for GERD, a primary cause of
chronic cough [20,25,29-31]. In the present study, leso-
gaberan was found to be an effective antitussive agent,
preventing citric acid evoked coughing in conscious
Figure 3 Effects of GABAB receptor agonists on citric acid evoked coughing. Each bar represents the mean ± sem of 3–15
experiments. An asterisk (*) indicates a significant reduction in the number of cumulative coughs relative to vehicle control (p < 0.05).
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incident sedative effects or respiratory depression. We
found this compound was as potent and effective as
baclofen, a GABAB receptor agonist used clinically for
the treatment of several disorders. Unlike lesogaberan,
however, the antitussive effects of baclofen were accom-
panied by undesirable side effects, including sedation, res-
piratory depression and a trend towards a decrease in
peak cough pressures. Based on these results, we concludeTable 1 Effects of GABAB agonists on the percentage of anim
expiratory pressures during cough
Treatment n Time to 1st
Cough (min)
Vehicle control 15 2.0±03
0.3 mg/ kg baclofen 3 2.4±0.6
3 mg/ kg baclofen 6 1.4±0.3
3 mg/ kg SKF97541 5 2.7±1.0
0.3 mg/ kg 3-APPiA 4 2.8±0.7
3 mg/ kg 3-APPiA 7 3.3±0.7
1 mg/ kg lesogaberan 5 1.7±0.2
3 mg/ kg lesogaberan 8 2.1±0.6
10 mg/ kg lesogaberan 8 3.0±0.6
The data are presented as the %animals coughing or as the mean ± sem of n expe
design. The time to first cough was measured during challenges with 0.3 M citric ac
the first 5 coughs evoked during challenge, regardless of citric acid concentration. A
in vehicle treated animals (p < 0.05).that lesogaberan may hold promise for the treatment of
acute and chronic cough and may have a better side effect
profile than baclofen.
The four GABAB receptor agonists used in this study
are essentially identical in receptor pharmacological pro-
file. All are selective GABAB receptor agonists, with
SKF97541, 3-APPiA and lesogaberan sharing structural
similarities. Key to their differential side effect profile,
however, is their susceptibility to uptake by GABAals coughing, time to onset of coughing and on peak




1144±102% 27% (4/ 15) 93% (14/ 15)
837±187% 100% (3/ 3) 100% (3/ 3)
705±110% 0% (0/ 6)* 50% (3/ 6)
852±92% 0% (0/ 5)* 60% (3/ 5)
762±121% 0% (0/ 5)* 80% (4/ 5)
986±120% 0% (0/ 7)* 57% (4/ 7)
1426±142% 0% (0/ 5)* 80% (4/ 5)
1100±144% 13% (1/ 8) 63% (5/ 8)
855±99% 0% (0/ 8)* 50% (4/ 8)
riments where n is a single animal studied in a non paired experimental
id. The peak to peak (P-P) pressures associated with cough were measured for
n asterisk (*) indicates a statistically significant difference from that observed
Canning et al. Cough 2012, 8:7 Page 5 of 7
http://www.coughjournal.com/content/8/1/7transporters [23-25]. Baclofen and SKF97541 are not
transported, whereas both 3-APPiA and lesogaberan are
substrates for GAT. Thus, the site of action for the latter
2 compounds is thought to be limited to peripheral loca-
tions and perhaps central locations with limited GAT ex-
pression [19,25]. The marked respiratory depression and
lethargy induced by SKF97541 and baclofen but not by
lesogaberan and 3-APPiA we observed are consistent with
the known susceptibility to uptake of these compounds.
Our results confirm and extend the studies by Bolser
et al. [27,28,34], who reported that both baclofen and
3-APPiA prevented coughing in guinea pigs and cats.
Because 3-APPiA was more effective administered pe-
ripherally than centrally, the authors concluded that
GABAB receptor agonists prevent cough at least in part
through peripheral sites of action. But a central site of
action of these drugs cannot be entirely dismissed. We
found that intraperitoneally administered baclofen inhi-
bits cough [33], but we also reported that baclofen
microinjected into the nTS inhibits cough in anesthe-
tized guinea pigs [35]. Bolser et al. concluded that
baclofen works primarily via central effects [28,34].
Similarly, Callaway and King [36] found that baclofen
inhalation prevented citric acid induced alterations in
respiratory pattern (possibly by inhibiting broncho-
spasm) but was without effect on citric acid induced
cough. Perhaps cell groupings in the brainstem, access-
ible to peripherally administered agonists and on the
fringe of the blood brain barrier, are targeted by these
drugs. For a central site of action to be viable, agonists
such as 3-APPiA and lesogaberan must penetrate brain-
stem regions relevant to cough and attain sufficient con-
centrations to prevent or blunt synaptic transmission.
There is conflicting evidence relating to blood-borne ac-
cess and GABA uptake mechanisms in nTS [37-43].
GABAB receptor activation might prevent coughing
through peripheral inhibitory effects on bronchopul-
monary vagal afferent nerves. The vagal afferent nerves
regulating cough in guinea pigs are C-fibers arising from
the jugular ganglia, and cough receptors, terminating in
the larynx, trachea and mainstem bronchi and with cell
bodies in the nodose ganglia [32,44]. Both of these vagal
afferent nerve subtypes are responsive to acid but largely
insensitive to changes in airway luminal pressure, stretch
or airway smooth muscle contraction. The cough recep-
tors are, however, insensitive to capsaicin. Given that
Bolser et al. studied the antitussive effects of baclofen
and 3-APPiA with capsaicin as the tussive stimulus, the
available data would suggest that if GABAB receptor
agonists are working peripherally, they act at least in
part through effects on airway vagal C-fiber terminals
[27,28]. In fact, there is functional evidence to suggest
that the vagal C-fibers regulating cough express GABAB
receptors on their peripheral terminals [45,46], but asyet, there is no evidence to suggest their activation
would prevent action potential discharge. Interestingly,
however, there are several studies showing direct inhibi-
tory effects of GABAB receptor agonists on the excitabi-
lity of vagal afferent nerves, including those innervating
the stomach and esophagus [47-50].
Non-neuronal sites of action for GABAB receptor ago-
nists are also possible. Acid evoked cough may be mast
cell dependent, and mast cell activation may trigger or
at least modulate subsequently evoked cough [51,52].
GABAB receptor agonists can attenuate allergen-induced
inflammation, perhaps through effects on mast cell acti-
vation [53,54]. GABAB receptors on non-neural airway
cells has also been documented, including airway
smooth muscle and epithelium [55,56], and we have
described a transduction pathway dependent upon acti-
vation of chemosensory epithelial cells [57]. Endogenous
GABA in the lung may also regulate cough [58]. Finally,
GABAB receptor agonists have also been shown to at-
tenuate parasympathetic-cholinergic responses in the
airways, which might also indirectly attenuate cough
responses [59-61]. In general, however, these non-neural
influences on cough would seem more likely to be mo-
dulatory than essential to evoked cough. Bronchospasm
is not an effective stimulus for cough, and bronchodila-
tors have modest, variable effects on evoked cough [44].
GABAB receptor agonists may hold promise in the
treatment of GERD due to their ability to prevent
TLESR, the primary physiologic process responsible for
reflux [15,17,18,62,63]. Compounds such as lesogaberan
may offer a distinct advantage over conventional thera-
peutic approaches to GERD inasmuch as proton pump
inhibitors and histamine H2 receptor antagonists do not
prevent reflux, but rather, reduce the acid content of
gastric fluid. While acid is thought to be the major trig-
ger of symptoms and pathology in GERD, other compo-
nents of refluxate such as pepsin likely contribute to the
pathophysiology of this disease [64,65]. GERD is also a
major cause of chronic cough [1,2]. Indeed, cough may
be the only presenting symptom of GERD in some
patients. The ability of compounds such as lesogaberan
to prevent coughing evoked directly from the airways is
another potential therapeutic advantage of GABAB re-
ceptor agonists in the treatment of GERD. These attri-
butes along with the limited side effect profile of
lesogaberan relative to that of baclofen provides impetus
for continued study of this compound as a treatment for
both GERD and chronic cough.
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